Table 6.
Counts and Distribution of Treatment Episodes.
| Biologic drugs | Row %
|
||||
|---|---|---|---|---|---|
| Number | MAX 00-06 (N=270,458) | TennCare 98-07 (N=36,786) | PAAD/PACE 98-06 (N=28,017) | KPNC 98-07 (N=72,058) | |
| Etanercept | 19,960 | 70.4 | 8.2 | 4.4 | 17.1 |
| Infliximab | 15,748 | 78.5 | 5.6 | 3.7 | 12.2 |
| AdalimuabAdalimumab | 11,527 | 78.4 | 5.9 | 3.3 | 12.4 |
| Anakinra | 2,056 | 86.6 | 7.7 | 2.3 | 3.4 |
| Rituximab | 1,227 | 72.5 | 3.7 | 7.5 | 16.3 |
| Alefacept | 860 | 90.4 | 2.8 | 0.2 | 6.6 |
| Efalizumab | 663 | 83.3 | 7.5 | 0.3 | 8.9 |
| Abatacept | 182 | 45.6 | 0.0 | 0.6 | 53.9 |
| Total biologic episodes | 52,223 | 75.7 | 6.6 | 3.8 | 13.9 |
|
| |||||
| Comparison drugs (across all diseases) | |||||
|
| |||||
| Methotrexate | 52,374 | 66.0 | 9.2 | 5.9 | 18.8 |
| Hydroxychloroquine | 32,708 | 63.5 | 9.9 | 4.7 | 21.9 |
| 5-ASA | 24,302 | 55.4 | 8.9 | 9.9 | 25.8 |
| Sulfasalazine | 18,790 | 57.8 | 8.2 | 4.3 | 29.7 |
| Large dose topical steroid* | 17,758 | 67.5 | 10.3 | 10.4 | 11.9 |
| Leflunomide | 15,240 | 62.7 | 9.3 | 6.2 | 21.9 |
| Phototherapy | 10,894 | 41.3 | 3.5 | 3.5 | 51.7 |
| Azathioprine | 8,225 | 55.4 | 10.6 | 3.6 | 30.5 |
| 6-Mercaptopurine | 4,273 | 55.6 | 10.0 | 2.7 | 31.7 |
| Retinoid | 4,249 | 63.5 | 7.9 | 5.1 | 23.5 |
| Total comparison episodes | 341,048 | 63.4 | 9.8 | 7.6 | 19.0 |
*
Large quantity topical steroid relevant to the psoriasis comparisons only.